Guggenheim analyst Michael Schmidt raised the firm’s price target on BeiGene (ONC) to $348 from $345 and keeps a Buy rating on the shares after updating the firm’s model for Q4 results. Management highlighted a number of upcoming data disclosures, including an interim analysis of progression-free survival for the Phase 3 MANGROVE study for Brukinsa in TN mantle cell lymphoma in the second half of 2025, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene price target raised to $348 from $288 at Citizens JMP
- BeiGene’s Strong Financial Performance and Strategic Positioning Earns Buy Rating
- BeiGene Faces Potential Tax Risks Amid Corporate Restructuring: Stakeholders Urged to Review SEC Filings
- BeiGene Reports Strong 2024 Financial Growth and Strategic Advancements
- BeiGene’s Earnings Call: Strong Growth and Market Leadership